Eastham et al. have recently reported — in the Journal of Clinical Oncology — results from a randomized Phase III trial of the surgical treatment of men with high-risk forms of localized prostate cancer. … READ MORE …
Filed under: Management, Treatment | Tagged: "high risk", ADT, androgen, chemohormonal, chemotherapy, CHT, deprivation, localized, neoadjuvant, prostatectomy, radical, trial | 1 Comment »
With the third Advanced Prostate Cancer Consensus Conference (APCCC) due to start here in Basel, Switzerland, this morning, there is an important new set of data that will help to inform some of the discussions. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: adjuvant, advanced, chemotherapy, radiation, SPCG-13, trial | 2 Comments »
In another presentation from the ESMO meeting in Madrid, Spain, Fizazi et al. presented data from the randomized CABA-DOC trial exploring patients’ preferences for either docetaxel or cabazitaxel as a first-line form of chemotherapy. … READ MORE …
Filed under: Management, Treatment | Tagged: cabazitaxel, chemotherapy, choice, docetaxel, preference, taxane | 2 Comments »
So the results from the CHAARTED and STAMPEDE trials over the past few years have re-ignited debate over the appropriateness of early use of chemotherapy in the treatment of aggressive forms of prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: "high risk", aggressive, chemotherapy, early, outcomes | 1 Comment »
TAPS stands for “taxane acute pain syndrome”. It is a recognized side effect of treatment with taxanes like docetaxel and it is usually characterized by muscular pain (myalgia) and joint pain (arthralgia) that starts about 24 to 48 hours after taxane treatment and then lasts for up to about 7 days. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Risk, Treatment | Tagged: chemotherapy, pain, TAPS, taxane, Treatment | 9 Comments »
One of the small number of major prostate cancer presentations at the ASCO meeting this year comes from the so-called PRINCE trial of intermittent chemotherapy in men with castration-resistant prostate cancer (CRPC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: chemotherapy, continuous, docetaxel, intermittent, outcome | 5 Comments »
A paper presented yesterday at the now-completed annual meeting of the American Urological Association has given us new data on the role of adjuvant chemotherapy alone in the treatment of men with high-risk prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: "high risk", adjuvant, chemotherapy, docetaxel, prostatectomy | Leave a comment »
A combined Russian and German research team has provided some interesting preliminary information on the use of neoadjuvant, low-dose docetaxel-based chemotherapy in treatment of intermediate- and high-risk patients prior to radical prostatectomy. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: "high risk", chemotherapy, intermediate risk, localized, prostatectomy, radical | Leave a comment »
A research team working just down the street here in Philadelphia thinks cabazitaxel (Jevtana) may have expanded potential in treatment of some men with castration-resistant prostate cancer (CRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: cabazitaxel, castration-resistant, chemotherapy, CRPC | 10 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 